Literature DB >> 24604593

Amyloid imaging in depression: a predictor of Alzheimer's disease?

Valle Camacho1, Alberto Lleó.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24604593     DOI: 10.1007/s00259-014-2741-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  42 in total

1.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

2.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

3.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

4.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

5.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

6.  Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.

Authors:  Victor L Villemagne; Rachel S Mulligan; Svetlana Pejoska; Kevin Ong; Gareth Jones; Graeme O'Keefe; J Gordon Chan; Kenneth Young; Henri Tochon-Danguy; Colin L Masters; Christopher C Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-08       Impact factor: 9.236

7.  Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.

Authors:  Kuan-Yi Wu; Ing-Tsung Hsiao; Cheng-Sheng Chen; Chia-Hsiang Chen; Chia-Ju Hsieh; Yau-Yau Wai; Chee-Jen Chang; Hsiao-Jung Tseng; Tzue-Chen Yen; Chia-Yih Liu; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04       Impact factor: 9.236

8.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease.

Authors:  Kerryn E Pike; Greg Savage; Victor L Villemagne; Steven Ng; Simon A Moss; Paul Maruff; Chester A Mathis; William E Klunk; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2007-10-10       Impact factor: 13.501

Review 9.  Reassessing the amyloid cascade hypothesis of Alzheimer's disease.

Authors:  Sanjay W Pimplikar
Journal:  Int J Biochem Cell Biol       Date:  2008-12-30       Impact factor: 5.085

Review 10.  Molecular tools for assessing human depression by positron emission tomography.

Authors:  Donald F Smith; Steen Jakobsen
Journal:  Eur Neuropsychopharmacol       Date:  2009-06-06       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.